JP2008538812A5 - - Google Patents

Download PDF

Info

Publication number
JP2008538812A5
JP2008538812A5 JP2008506405A JP2008506405A JP2008538812A5 JP 2008538812 A5 JP2008538812 A5 JP 2008538812A5 JP 2008506405 A JP2008506405 A JP 2008506405A JP 2008506405 A JP2008506405 A JP 2008506405A JP 2008538812 A5 JP2008538812 A5 JP 2008538812A5
Authority
JP
Japan
Prior art keywords
bound
sdldl
amount
particles
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008506405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008538812A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2006/000425 external-priority patent/WO2006110082A1/en
Publication of JP2008538812A publication Critical patent/JP2008538812A/ja
Publication of JP2008538812A5 publication Critical patent/JP2008538812A5/ja
Withdrawn legal-status Critical Current

Links

JP2008506405A 2005-04-11 2006-04-10 方法 Withdrawn JP2008538812A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0500808 2005-04-11
PCT/SE2006/000425 WO2006110082A1 (en) 2005-04-11 2006-04-10 A method and a kit for diagnosing type 2 diabetes, metabolic syndrome, sub clinical atherosclerosis, myocardial infarct, stroke or clinical manifestations of diabetes.

Publications (2)

Publication Number Publication Date
JP2008538812A JP2008538812A (ja) 2008-11-06
JP2008538812A5 true JP2008538812A5 (https=) 2009-04-09

Family

ID=37087285

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008506405A Withdrawn JP2008538812A (ja) 2005-04-11 2006-04-10 方法

Country Status (5)

Country Link
US (1) US20090280501A1 (https=)
EP (1) EP1872138A1 (https=)
JP (1) JP2008538812A (https=)
CN (1) CN101166981A (https=)
WO (1) WO2006110082A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2517572C (en) * 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
EP2015077B1 (en) * 2006-05-01 2012-10-31 DENKA SEIKEN Co., Ltd. Method for detection of familial combined hyperlipidemia
JP2008116248A (ja) * 2006-11-01 2008-05-22 Yoshikimi Kikuchi 子宮体癌の検出方法
AT505727B1 (de) * 2007-09-04 2009-06-15 Univ Innsbruck Verfahren zur diagnose des metabolischen syndroms
KR20110086074A (ko) * 2008-10-20 2011-07-27 리포사이언스, 인크. 지질단백질 인슐린 저항성 지표 및 이와 관련된 방법, 시스템 및 이를 생성하기 위한 컴퓨터 프로그램
JP2010190804A (ja) * 2009-02-19 2010-09-02 Biomarker Science:Kk 動脈硬化改善・予防効果の評価方法及び評価用キット、並びに、物質のスクリーニング方法
US20110008901A1 (en) * 2009-07-07 2011-01-13 Kiernan Urban A Apolipoprotein ciii in pre- and type 2 diabetes
CN103299192B (zh) * 2010-09-21 2016-05-11 普罗蒂阿米克斯国际有限公司 与糖尿病前期、糖尿病以及糖尿病相关病症相关的生物标记
CN102565416A (zh) * 2010-12-27 2012-07-11 中国科学院上海生命科学研究院 载脂蛋白a1作为糖尿病标志物的应用
US8557513B2 (en) * 2011-06-27 2013-10-15 Biocrine Ab Methods for treating and/or limiting development of diabetes
KR101355394B1 (ko) 2011-08-03 2014-01-29 서울대학교산학협력단 임신성 당뇨 조기 진단 정보를 제공하는 방법 및 임신성 당뇨 조기 진단 정보를 제공하는데 사용되는 임신성 당뇨 모니터링, 진단 및 스크리닝용 키트
CN103308670B (zh) * 2012-03-08 2017-06-09 思芬构技术有限公司 用于预测对象患糖尿病和/或代谢综合征的风险的方法
CN103376323A (zh) * 2012-04-25 2013-10-30 中国科学院上海生命科学研究院 载脂蛋白c-iii作为肥胖型糖尿病标志物的应用
CN107884467A (zh) * 2017-10-31 2018-04-06 北京毅新博创生物科技有限公司 改善质谱检测糖基结晶的方法及产品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064008A2 (en) * 2000-03-03 2001-09-07 Smithkline Beecham Biologicals S.A. Vaccine for the treatment of artherosclerosis
US20040137521A1 (en) * 2001-06-05 2004-07-15 Jamila Najib-Fruchart Method for apo clll measurement in apo b and non apo b containing particles
JP4593026B2 (ja) * 2001-07-18 2010-12-08 栄研化学株式会社 SmalldenseLDLの測定方法
WO2003029829A1 (en) * 2001-10-01 2003-04-10 The Texas A & M University System Lipoprotein fingerprinting method
ATE505731T1 (de) * 2002-12-06 2011-04-15 Denka Seiken Kk Verfahren zur quantifizierung von kleinen lipoproteinen mit geringer dichte

Similar Documents

Publication Publication Date Title
Maisel et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial
Ukena et al. Diagnostic and prognostic validity of different biomarkers in patients with suspected myocarditis
Sumida et al. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease
JP2008538812A5 (https=)
Guo et al. Association between microalbuminuria and cardiovascular disease in type 2 diabetes mellitus of the Beijing Han nationality
CN103403549B (zh) 败血症的预后的预测方法
Berezin et al. Pattern of circulating microparticles in chronic heart failure patients with metabolic syndrome: Relevance to neurohumoral and inflammatory activation
EP1931990A2 (en) Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
KR20170134641A (ko) 간 질환의 병태를 판별하는 방법
Cai et al. Biomarkers of oxidation stress, inflammation, necrosis and apoptosis are associated with hepatitis B-related acute-on-chronic liver failure
MX2014002146A (es) Métodos y composiciones para diagnóstico y pronóstico de lesión renal e insuficiencia renal.
JP5415520B2 (ja) 最大酸素消費量低下の予測のためのプロ−エンドセリン−1
WO2011092219A1 (en) Biomarkers of cardiovascular disease including lrg
Peng et al. Levels of B-type natriuretic peptide in chronic heart failure patients with and without diabetes mellitus
Al-Saffar et al. Microalbuminuria in non-diabetic patients with unstable angina/non ST-segment elevation myocardial infarction
RU2019106326A (ru) Гистоны и/или proadm в качестве маркеров, свидетельствующих об органной дисфункции
Hsu et al. Lymphocyte-to-monocyte ratio predicts mortality in cirrhotic patients with septic shock
Ma et al. High mean platelet volume is associated with worse outcomes in patients with HBV-related decompensated cirrhosis
Wang et al. Estimating systemic fibrosis by combining galectin-3 and ST2 provides powerful risk stratification value for patients after acute decompensated heart failure
Jin et al. 2D shear wave elastography combined with MELD improved prognostic accuracy in patients with acute-on-chronic hepatitis B liver failure
CA2814702C (en) Body fluid bin1 as a marker of cardiac health
Liang et al. Clinical utility of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 concentrations in the assessment of liver fibrosis due to chronic hepatitis B
Hermann-Arnhof et al. N-terminal pro-B-type natriuretic peptide as an indicator of possible cardiovascular disease in severely obese individuals: comparison with patients in different stages of heart failure
Yuksel et al. Evaluation of triglyceride-glucose index in coronary slow flow patients
CN110988351B (zh) 血管细胞黏附分子在制备抑郁症诊断治疗相关产品的用途